Fact Sheet for Healthcare Providers: BioFire ® Respiratory Panel 2.1 (RP2.1) – BioFire Diagnostics, LLC

Source: U.S. Food and Drug Administration (FDA). Published: 5/1/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the BioFire ® Respiratory Panel 2.1 (RP2.1), which received an Emergency Use Authorization from the Food and Drug Administration on May 1, 2020. The BioFire® RP2.1 test is authorized for use on using respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - Category: International Medicine & Public Health Source Type: news